Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
Excerpt from the Press Release:
Valo’s Opal Computational Platform™ being used to select a patient subset within non-proliferative diabetic retinopathy patients at high risk of progressing toward vision-threatening disease
BOSTON, Aug. 18, 2022 /PRNewswire/ — Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study – a multi-center randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of oral OPL-0401 in patients with mild, moderate, and severe non-proliferative diabetic retinopathy (NPDR). OPL-0401 is an investigational small molecule Rho kinase (ROCK) 1/2 inhibitor and a potential first-in-class oral option for patients with NPDR, where the current treatment options are intravitreal injections, surgery, or laser treatment.
The Spectra study was designed using Valo’s Opal Computational Platform which enabled real-world data analyses intended to identify patient populations that could potentially benefit most from early treatment. Further, the study is designed to enable data capture that can support not only the expansion of Valo’s data lake but also subsequent analyses for further patient characterization, response prediction, and beyond
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?